1 Study Coverage 1.1 VEGF Inhibitor Drugs Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Introduction 1.2 Global VEGF Inhibitor Drugs Outlook 2017 VS 2022 VS 2028 1.2.1 Global VEGF Inhibitor Drugs Market Size for the Year 2017-2028 1.2.2 Global VEGF Inhibitor Drugs Market Size for the Year 2017-2028 1.3 VEGF Inhibitor Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States VEGF Inhibitor Drugs in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of VEGF Inhibitor Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 VEGF Inhibitor Drugs Market Dynamics 1.4.1 VEGF Inhibitor Drugs Industry Trends 1.4.2 VEGF Inhibitor Drugs Market Drivers 1.4.3 VEGF Inhibitor Drugs Market Challenges 1.4.4 VEGF Inhibitor Drugs Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 VEGF Inhibitor Drugs by Type 2.1 VEGF Inhibitor Drugs Market Segment by Type 2.1.1 Tyrosine Kinase Inhibitors 2.1.2 Monoclonal Antibodies 2.1.3 Others 2.2 Global VEGF Inhibitor Drugs Market Size by Type (2017, 2022 & 2028) 2.3 Global VEGF Inhibitor Drugs Market Size by Type (2017-2028) 2.4 United States VEGF Inhibitor Drugs Market Size by Type (2017, 2022 & 2028) 2.5 United States VEGF Inhibitor Drugs Market Size by Type (2017-2028) 3 VEGF Inhibitor Drugs by Application 3.1 VEGF Inhibitor Drugs Market Segment by Application 3.1.1 Oncology 3.1.2 Ophthalmology 3.1.3 Others 3.2 Global VEGF Inhibitor Drugs Market Size by Application (2017, 2022 & 2028) 3.3 Global VEGF Inhibitor Drugs Market Size by Application (2017-2028) 3.4 United States VEGF Inhibitor Drugs Market Size by Application (2017, 2022 & 2028) 3.5 United States VEGF Inhibitor Drugs Market Size by Application (2017-2028) 4 Global VEGF Inhibitor Drugs Competitor Landscape by Company 4.1 Global VEGF Inhibitor Drugs Market Size by Company 4.1.1 Top Global VEGF Inhibitor Drugs Companies Ranked by Revenue (2021) 4.1.2 Global VEGF Inhibitor Drugs Revenue by Player (2017-2022) 4.2 Global VEGF Inhibitor Drugs Concentration Ratio (CR) 4.2.1 VEGF Inhibitor Drugs Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of VEGF Inhibitor Drugs in 2021 4.2.3 Global VEGF Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global VEGF Inhibitor Drugs Headquarters, Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Type 4.3.1 Global VEGF Inhibitor Drugs Headquarters and Area Served 4.3.2 Global VEGF Inhibitor Drugs Companies Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into VEGF Inhibitor Drugs Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States VEGF Inhibitor Drugs Market Size by Company 4.5.1 Top VEGF Inhibitor Drugs Players in United States, Ranked by Revenue (2021) 4.5.2 United States VEGF Inhibitor Drugs Revenue by Players (2020, 2021 & 2022) 5 Global VEGF Inhibitor Drugs Market Size by Region 5.1 Global VEGF Inhibitor Drugs Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global VEGF Inhibitor Drugs Market Size by Region (2017-2028) 5.2.1 Global VEGF Inhibitor Drugs Market Size by Region: 2017-2022 5.2.2 Global VEGF Inhibitor Drugs Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America VEGF Inhibitor Drugs Market Size YoY Growth 2017-2028 6.1.2 North America VEGF Inhibitor Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 United States 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific VEGF Inhibitor Drugs Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific VEGF Inhibitor Drugs Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 China Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.3 Europe 6.3.1 Europe VEGF Inhibitor Drugs Market Size YoY Growth 2017-2028 6.3.2 Europe VEGF Inhibitor Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America VEGF Inhibitor Drugs Market Size YoY Growth 2017-2028 6.4.2 Latin America VEGF Inhibitor Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa VEGF Inhibitor Drugs Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa VEGF Inhibitor Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Pfizer 7.1.1 Pfizer Company Details 7.1.2 Pfizer Business Overview 7.1.3 Pfizer VEGF Inhibitor Drugs Introduction 7.1.4 Pfizer Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.1.5 Pfizer Recent Development 7.2 Novartis AG 7.2.1 Novartis AG Company Details 7.2.2 Novartis AG Business Overview 7.2.3 Novartis AG VEGF Inhibitor Drugs Introduction 7.2.4 Novartis AG Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.2.5 Novartis AG Recent Development 7.3 GlaxoSmithKline plc 7.3.1 GlaxoSmithKline plc Company Details 7.3.2 GlaxoSmithKline plc Business Overview 7.3.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Introduction 7.3.4 GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.3.5 GlaxoSmithKline plc Recent Development 7.4 Sanofi 7.4.1 Sanofi Company Details 7.4.2 Sanofi Business Overview 7.4.3 Sanofi VEGF Inhibitor Drugs Introduction 7.4.4 Sanofi Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.4.5 Sanofi Recent Development 7.5 AstraZeneca plc 7.5.1 AstraZeneca plc Company Details 7.5.2 AstraZeneca plc Business Overview 7.5.3 AstraZeneca plc VEGF Inhibitor Drugs Introduction 7.5.4 AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.5.5 AstraZeneca plc Recent Development 7.6 Bristol-Myers-Squibb Company 7.6.1 Bristol-Myers-Squibb Company Company Details 7.6.2 Bristol-Myers-Squibb Company Business Overview 7.6.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Introduction 7.6.4 Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.6.5 Bristol-Myers-Squibb Company Recent Development 7.7 Genentech, Inc. (Roche) 7.7.1 Genentech, Inc. (Roche) Company Details 7.7.2 Genentech, Inc. (Roche) Business Overview 7.7.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Introduction 7.7.4 Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.7.5 Genentech, Inc. (Roche) Recent Development 7.8 Merck & Co., Inc. 7.8.1 Merck & Co., Inc. Company Details 7.8.2 Merck & Co., Inc. Business Overview 7.8.3 Merck & Co., Inc. VEGF Inhibitor Drugs Introduction 7.8.4 Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.8.5 Merck & Co., Inc. Recent Development 7.9 Bayer AG 7.9.1 Bayer AG Company Details 7.9.2 Bayer AG Business Overview 7.9.3 Bayer AG VEGF Inhibitor Drugs Introduction 7.9.4 Bayer AG Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.9.5 Bayer AG Recent Development 7.10 Eli Lilly & Company 7.10.1 Eli Lilly & Company Company Details 7.10.2 Eli Lilly & Company Business Overview 7.10.3 Eli Lilly & Company VEGF Inhibitor Drugs Introduction 7.10.4 Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2017-2022) 7.10.5 Eli Lilly & Company Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. VEGF Inhibitor Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. VEGF Inhibitor Drugs Market Trends Table 3. VEGF Inhibitor Drugs Market Drivers Table 4. VEGF Inhibitor Drugs Market Challenges Table 5. VEGF Inhibitor Drugs Market Restraints Table 6. Global VEGF Inhibitor Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States VEGF Inhibitor Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global VEGF Inhibitor Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States VEGF Inhibitor Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top VEGF Inhibitor Drugs Companies in Global Market, Ranking by Revenue (2021) Table 11. Global VEGF Inhibitor Drugs Revenue by Player, (US$ Million), 2017-2022 Table 12. Global VEGF Inhibitor Drugs Revenue Share by Player, 2017-2022 Table 13. Global VEGF Inhibitor Drugs Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global VEGF Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2021) Table 15. Top Players of VEGF Inhibitor Drugs in Global Market, Headquarters and Area Served Table 16. Companies Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into VEGF Inhibitor Drugs Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top VEGF Inhibitor Drugs Players in United States Market, Ranking by Revenue (2021) Table 20. United States VEGF Inhibitor Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States VEGF Inhibitor Drugs Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global VEGF Inhibitor Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global VEGF Inhibitor Drugs Market Size by Region (2017-2022) & (US$ Million) Table 24. Global VEGF Inhibitor Drugs Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America VEGF Inhibitor Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific VEGF Inhibitor Drugs Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe VEGF Inhibitor Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa VEGF Inhibitor Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa VEGF Inhibitor Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Pfizer Company Details Table 31. Pfizer Business Overview Table 32. Pfizer VEGF Inhibitor Drugs Product Table 33. Pfizer Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 34. Pfizer Recent Development Table 35. Novartis AG Company Details Table 36. Novartis AG Business Overview Table 37. Novartis AG VEGF Inhibitor Drugs Product Table 38. Novartis AG Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 39. Novartis AG Recent Development Table 40. GlaxoSmithKline plc Company Details Table 41. GlaxoSmithKline plc Business Overview Table 42. GlaxoSmithKline plc VEGF Inhibitor Drugs Product Table 43. GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 44. GlaxoSmithKline plc Recent Development Table 45. Sanofi Company Details Table 46. Sanofi Business Overview Table 47. Sanofi VEGF Inhibitor Drugs Product Table 48. Sanofi Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 49. Sanofi Recent Development Table 50. AstraZeneca plc Company Details Table 51. AstraZeneca plc Business Overview Table 52. AstraZeneca plc VEGF Inhibitor Drugs Product Table 53. AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 54. AstraZeneca plc Recent Development Table 55. Bristol-Myers-Squibb Company Company Details Table 56. Bristol-Myers-Squibb Company Business Overview Table 57. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Table 58. Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 59. Bristol-Myers-Squibb Company Recent Development Table 60. Genentech, Inc. (Roche) Company Details Table 61. Genentech, Inc. (Roche) Business Overview Table 62. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Table 63. Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 64. Genentech, Inc. (Roche) Recent Development Table 65. Merck & Co., Inc. Company Details Table 66. Merck & Co., Inc. Business Overview Table 67. Merck & Co., Inc. VEGF Inhibitor Drugs Product Table 68. Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 69. Merck & Co., Inc. Recent Development Table 70. Bayer AG Company Details Table 71. Bayer AG Business Overview Table 72. Bayer AG VEGF Inhibitor Drugs Product Table 73. Bayer AG Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 74. Bayer AG Recent Development Table 75. Eli Lilly & Company Company Details Table 76. Eli Lilly & Company Business Overview Table 77. Eli Lilly & Company VEGF Inhibitor Drugs Product Table 78. Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2017-2022) & (US$ Million) Table 79. Eli Lilly & Company Recent Development Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources List of Figures Figure 1. VEGF Inhibitor Drugs Product Picture Figure 2. Global VEGF Inhibitor Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global VEGF Inhibitor Drugs Market Size 2017-2028 (US$ Million) Figure 4. United States VEGF Inhibitor Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States VEGF Inhibitor Drugs Market Size 2017-2028 (US$ Million) Figure 6. United States VEGF Inhibitor Drugs Market Share in Global 2017-2028 Figure 7. VEGF Inhibitor Drugs Report Years Considered Figure 8. Product Picture of Tyrosine Kinase Inhibitors Figure 9. Product Picture of Monoclonal Antibodies Figure 10. Product Picture of Others Figure 11. Global VEGF Inhibitor Drugs Market Share by Type in 2022 & 2028 Figure 12. Global VEGF Inhibitor Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 13. Global VEGF Inhibitor Drugs Market Share by Type (2017-2028) Figure 14. United States VEGF Inhibitor Drugs Market Share by Type in 2022 & 2028 Figure 15. United States VEGF Inhibitor Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 16. United States VEGF Inhibitor Drugs Market Share by Type (2017-2028) Figure 17. Product Picture of Oncology Figure 18. Product Picture of Ophthalmology Figure 19. Product Picture of Others Figure 20. Global VEGF Inhibitor Drugs Market Share by Application in 2022 & 2028 Figure 21. Global VEGF Inhibitor Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 22. Global VEGF Inhibitor Drugs Market Share by Application (2017-2028) Figure 23. United States VEGF Inhibitor Drugs Market Share by Application in 2022 & 2028 Figure 24. United States VEGF Inhibitor Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 25. United States VEGF Inhibitor Drugs Market Share by Application (2017-2028) Figure 26. North America VEGF Inhibitor Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 27. United States VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Canada VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Europe VEGF Inhibitor Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. Germany VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. France VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. U.K. VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Italy VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Russia VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Asia-Pacific VEGF Inhibitor Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 36. China VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Japan VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. South Korea VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. India VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Australia VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. China Taiwan VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Indonesia VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Thailand VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Malaysia VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Latin America VEGF Inhibitor Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 46. Mexico VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Brazil VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Argentina VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Middle East & Africa VEGF Inhibitor Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 50. Turkey VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Saudi Arabia VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. UAE VEGF Inhibitor Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Pfizer Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 54. Novartis AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 55. GlaxoSmithKline plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 56. Sanofi Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 57. AstraZeneca plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 58. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 59. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 60. Merck & Co., Inc. Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 61. Bayer AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 62. Eli Lilly & Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2017-2022) Figure 63. Bottom-up and Top-down Approaches for This Report Figure 64. Data Triangulation Figure 65. Key Executives Interviewed

Pfizer Novartis AG GlaxoSmithKline plc Sanofi AstraZeneca plc Bristol-Myers-Squibb Company Genentech, Inc. (Roche) Merck & Co., Inc. Bayer AG Eli Lilly & Company